Taking a Closer Look At Lipocine Inc. (LPCN) Following Its Recent Trade

0
17

Lipocine Inc.’s filing revealed that its Director Papapetropoulos Spyros acquired Company’s shares for reported $10217.0 on Nov 22. In the deal valued at $0.47 per share,21,739 shares were bought. As a result of this transaction, Papapetropoulos Spyros now holds 21,739 shares worth roughly $ 6739.09.


From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".

Sponsored


Then, Patel Mahesh V. bought 75,000 shares, generating $29,250 in total proceeds. Upon buying the shares at $0.39, the CEO and President now owns 1,478,090 shares.

Before that, Patel Mahesh V. bought 100,000 shares. Lipocine Inc. shares valued at $41,000 were divested by the CEO and President at a price of $0.41 per share. As a result of the transaction, Patel Mahesh V. now holds 1,403,090 shares, worth roughly $0.43 million.

Cantor Fitzgerald initiated its Lipocine Inc. [LPCN] rating to an Overweight in a research note published on Friday, June 24, 2021; the price target was $3. PT values the company’s stock at a premium of 89.67 to its Friday closing price. A number of analysts have revised their coverage, including Ladenburg Thalmann’s analysts, who increased its forecast for the stock in early December from “a Neutral” to “a Buy”. H.C. Wainwright also remained covering LPCN and reiterated its “Buy” recommendation on January 12, 2018. Canaccord Genuity revised its rating on January 11, 2018. It rated LPCN as “a Hold” which previously was an “a Buy”.

Price Performance Review of LPCN

On Friday, Lipocine Inc. [NASDAQ:LPCN] saw its stock fall -26.79% to $0.31. On the same session, the stock had its day’s lowest price of $0.2705, but rose to a high of $0.43. Over the last five days, the stock has lost -30.02%. Lipocine Inc. shares have fallen nearly -22.70% since the year began. Nevertheless, the stocks have fallen -79.50% over the past one year. While a 52-week high of $1.89 was reached on 01/19/23, a 52-week low of $0.36 was recorded on 03/10/23. SMA at 50 days reached $0.4887, while 200 days put it at $0.5706. A total of 1.97 million shares were traded, compared to the trading of 82500.0 shares in the previous session.

Levels Of Support And Resistance For LPCN Stock

The 24-hour chart illustrates a support level at 0.2420, which if violated will result in even more drops to 0.1765. On the upside, there is a resistance level at 0.4015. A further resistance level may holdings at 0.4955. The Relative Strength Index (RSI) on the 14-day chart is 20.86, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0465, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 85.17%. Stochastics %K at 20.40% indicates the stock is a holding.

How much short interest is there in Lipocine Inc.?

A steep rise in short interest was recorded in Lipocine Inc. stocks on Jan 12, 2023, dropping by 70000.0 shares to a total of 1.43 million shares. Yahoo Finance data shows the prior-month short interest on Dec 14, 2022 was 1.5 million shares. There was a decline of -4.9%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 1.66% of the overall stock float, the days-to-cover ratio (short ratio) fell to 9.92.

Lipocine Inc. [LPCN] – Who Are The Largest Shareholders?

In filings from The Vanguard Group, Inc., it is revealed that the company now owns 3,770,551 shares, or roughly 4.26% of the outstanding LPCN shares. In other words, the investor’s shares have risen by 2,016 from its previous 13-F filing of 3768535.0. Additionally, BlackRock Fund Advisors decreased -9.25% of its stake after which the total value it holdings stand at $653,025, while Wealth Effects LLC reduced -3.04% of its stake to hold $0.53 million in the firm. Over the last quarter, Geode Capital Management LLC sold -2,016 shares of Lipocine Inc., while Bridgeway Capital Management LLC sold 0 shares. At present, SSgA Funds Management, Inc. is holding 316,633 shares valued at $0.14 million. Two Sigma Investments LP owned 289,281 shares of the company at the time of its most recent 13F filing, worth $0.13 million.

According to FactSet, Lipocine Inc.’s share price will average $2.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 376.19 percent from its previous closing price of $0.42. Analysts expect Lipocine Inc. stock to reach the higher price of $2.00, while the lowest price estimate is $2.00. However, 1 analyst have rated LPCN stock as a Buy in their predictions for 2023.

LEAVE A REPLY

Please enter your comment!
Please enter your name here